Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2022 Nov 30;12:20660. doi: 10.1038/s41598-022-25203-4

Fibrin glue does not promote migration and proliferation of bone marrow derived mesenchymal stem cells in collagenic membranes: an in vitro study

Filippo Migliorini 1,✉,#, Julia Prinz 2,#, Jörg Eschweiler 1, Hanno Schenker 1, Christian Weber 1, Nicola Maffulli 3,4,5,✉, Sophie Lecouturier 1, Frank Hildebrand 1, Johannes Greven 1
PMCID: PMC9712600  PMID: 36450814

Abstract

During Autologous Matrix-Induced Chondrogenesis (AMIC), the membrane is often glued into the chondral defect. However, whether fibrin glue influences cells proliferation and migration remain unclear. This study evaluated the impact of fibrin glue addition to biologic membranes loaded with bone marrow-derived mesenchymal stem cells (B-MSCs). A porcine derived collagen membrane (Cartimaix, Matricel GmbH, Germany) was used. B-MSCs were harvested from three different unrelated donors. The membranes were embedded in mounting medium with DAPI (ABCAM, Cambridge, UK) and analysed at 1-, 2-, 3-, 4-, 6-, and at 8-week follow-up. The DAPI ties the DNA of the cell nucleus, emitting blue fluorescence. DAPI/nuclei signals were analysed with fluorescence microscopy at 100-fold magnification. The group without fibrin glue demonstrated greater migration of the B-MSCs within the membrane at week 4 (P < 0.001), 6 (P < 0.001), and 8 (P < 0.001). No difference was found at week 1, 2, and 3. The group without fibrin glue demonstrated greater proliferation of B-MSCs within the membrane. These differences were significant at week 1 (P = 0.02), 2 (P = 0.008), 3 (P = 0.0009), 4 (P < 0.0001), 6 (P < 0.0001), 8 (P < 0.0001). Concluding, in the present setting, the use of fibrin in a collagenic biomembrane impairs B-MSCs proliferation and migration in vitro.

Subject terms: Biotechnology, Diseases

Introduction

Chondral defects lead to chronic pain, reduced quality of life and sport activities, and osteoarthritis may result1,2. Conservative management often does produce long term improvement, and residual symptoms are common3,4. Bone marrow stimulating procedures have been advocated for chondral defects5–7, aiming to produce a continuum between subchondral bone and cartilage to enhance bone marrow-derived mesenchymal stem cells (B-MSCs) migration and proliferation into the chondral defect3,8. Autologous Matrix-Induced Chondrogenesis (AMIC) is a bone marrow stimulating procedure which demonstrated efficacy and safety for chondral defects of the knee and talus9,10. During AMIC, the blood clot from the microfractured subchondral bone is stabilised using a bioresorbable membrane. The fixation of this membrane into the defect can be problematic, and most clinical studies secured the AMIC membrane to the chondral defect using fibrin glue11–14. However, recently, the addition of fibrin glue to the membrane has been questioned. Several clinical studies on matrix-induced autologous chondrocyte implantation (mACI) demonstrated that the membrane remains stable even without formal fixation15–19. MACI is not considered a bone marrow stimulating procedure, as it delivers a membrane loaded with expanded autologous chondrocytes into the defect9,20. However, the nature of the membrane used in mACI is the same as in AMIC21,22. To the best of our knowledge, the impact of fibrin glue addition on B-MSCs migration and proliferation has not yet been investigated in vitro. The present investigation assessed the in vitro influence of the addition of fibrin glue to a B-MSCs loaded porcine derived collagen I/III membrane commonly employed in AMIC. The outcomes of interest were to compare migration and proliferation of B-MSCs with or without fibrin glue addition.

Methods

Study protocol

All procedures were performed in accordance with the relevant guidelines and regulations and approved by the ethical committee of the Medical Faculty of the University RWTH of Aachen (ID EK305-13). Informed consent was obtained from all subjects and/or their legal guardian(s). The methods used in the present study were already published in a previous in vitro study which evaluated the impact of fibrin glue on a chondrocyte loaded collagenic membrane23. Briefly, a resorbable collagen I/III porcine derived membrane (Cartimaix-collagen-membrane; Matricel GmbH, Germany) commonly employed in AMIC was used for the experiments. B-MSCs from three different unrelated donors were used: a 21 years old male, a 26 years old male, and a 33 years old female. The membranes were cut into 0.7 cm × 0.7 cm (area 0.49 cm2) in a sterile fashion. Overall, 72 membranes were used for the experiments: 36 non-glued and 36 membranes with fibrin glue (Tisseel, Baxter International Inc, Illinois, USA). Cell proliferation and migration was compared at 1-, 2-, 3-, 4-, 6-, and at 8-week follow-up. For each subject at every time point, 10 membrane sections were evaluated. This process is schematised in Fig. 1.

Figure 1.

Figure 1

Open in a new tab

Experimental set-up (N = 72).

MSCs processing

BM-MSCs of patients were isolated from the femoral head following the protocol of Li et al.24. Briefly, the femoral head was placed in a beaker and fixed with forceps. A cut surface was thoroughly rinsed several times with cell culture medium. The bone marrow in the cut surface was then loosened with forceps and again thoroughly rinsed with cell culture medium. The medium was placed a 50 ml Falcon tube (ThermoFisher Scientific, Waltham, MA, United States) and centrifuged at 1500 rpm for 10 min at room temperature (ca 20 °C). The obtained supernatant was aspirated, the pellet resuspended with cell culture medium, and seeded in a T75 cell culture flask (Thermo Fisher Scientific, Waltham, MA, USA). The next day, the cells were washed thoroughly three times with Phosphate-buffered saline (PBS) to remove the erythrocytes and other unwanted components. In that session, the medium suspension was also changed. To verify cell properties, flow cytometry was performed using the following FITC coupled anti human antibodies (all from Biorad, USA). Antibody anti CD19 (MCA2495F), CD34 (MCA547F), CD45 (MCA87F) were used as negative control, and CD 73 (MCA6068F), CD90 (MCA90F) and CD105 (MCA1557F) as positive control. The obtained data were processed using the software Cyflogic (CyFlo Ltd, Turku, Finland). The membranes were glued to the bottom of a 48-well cell culture dish by pipetting the glue (approx. 10 µL) to the bottom of the well, and the membrane was placed on top. Each membrane was seeded with B-MSCs on the porous side. Following trypsinization (Sigma-Aldrich/Merck KGaA, Darmstadt, Germany) and centrifugation (1500 rmp, 10 min), B-MSCs (third passage) were resuspended in a volume of 40 µl per membrane, and spread as homogenously as possible over the membranes at a density per membrane of approximately 100,000 B-MSCs per cm2. After cultivation for 2 h at 37 °C, 5% CO2 and a humidity of 90% in the incubator, the wells were filled up with cell culture medium. The cell culture medium was composed as follows: Dulbecco's Modified Eagle's Medium (DMEM) combined with 1 g/l d-Glucose (GlutaMax, low glucose, Gibco/Life Technologies, Paisley, UK), 10% fetal calf serum (FCS, Pan-Biotech, Aidenbach, Germany), 1% penicillin–streptomycin (Pen/Strep, Sigma-Aldrich/Merck KGaA, Darmstadt, Germany), and 1% Minimum Essential Media (MEM) combined with Non-Essential Amino Acids (Gibco/Life Technologies, Grand Island, NY, USA). The medium was changed every 3 days.

Experiments

At 1-, 2-, 3-, 4-, 6-, and at 8-weeks after seeding, a membrane was fixed in 4% paraformaldehyde (Merck Schuchardt OHG, Hohenbrunn, Germany) for 12 h. Afterwards, the membranes were dehydrated in an ascending alcohol series (1 h per cuvette) as follow: 70% ethanol, 80% ethanol, 96% ethanol, 100% ethanol (2×), and xylene (3×). Subsequently, the membranes were embedded in paraffin (Sakura Finetek Europe B.V., Alphen aan den Rijn, Netherlands) and cooled to − 10 °C. 3 µm sized cuts were prepared on a microtome (Schlittenmikrotom PFM Slide 4003E, PFM Medical AG, Cologne, Germany). To allow better adherence on the specimen slides, the cuts were heated at 60 °C for an hour. The paraffin of the slices was removed with xylol (Otto Fischar GmbH&Co KG, Saarbrücken, Germany) and afterwards the slices were carefully rehydrated with a descending alcohol series as follow: xylene (3×), 100% ethanol (2×), 96% ethanol, 80% ethanol, 70% ethanol, distilled water (5 min per cuvette). The membranes were embedded in Mounting Medium with DAPI (ABCAM, Cambridge, UK) and photographed on the fluorescence microscope (DM/RX, Leica, Wetzlar, Germany). The DAPI contained in the mounting medium ties the DNA of the cell nucleus and emits a blue fluorescence, allowing to detect how the cells in the membrane have spread.

Outcomes of interest

The outcomes of interest were (1) to evaluate cell migration and (2) cell proliferation within the porous membrane layer. DAPI/nuclei signals were analysed with fluorescence microscope at 100-fold magnification and the software Image J version 1.51 (National Institutes of Health, US). Migration was expressed as the percent of cell ingrowth within the overall thickness of the membrane. The cells which migrated in the deepest layer of the membrane was used a reference. Proliferation refers to the number of cells per mm3.

Statistics

The statistics analyses were performed using the IBM SPSS Statistics version 28.0 (IBM Corporation, Armonk NY, USA). The Shapiro–Wilk test was performed to investigate data distribution. For normally distributed variables the t-test (Welch) was used, the Mann Whitney U test for non-parametric data.

Ethical approval

The present study was approved by the ethical committee of the Medical Faculty of the University RWTH of Aachen (ID EK305-13).

Results

Flow cytometry of isolated B-MSCs

The isolated B-MSCs showed a clear positive FITC signal in flowcytometry histogram overlays using the Cyflogic software (Fig. 2). Negative controls of CD 19, CD34, and CD45 showed no positive FITC signal.

Figure 2.

Figure 2

Open in a new tab

Flowcytometric evaluation of isolated B-MSCs with positive controls of CD73, CD90, and CD105.

Migration

The group without fibrin glue demonstrated greater migration of the B-MSCs within the membrane at week 4 (P < 0.001), 6 (P < 0.001), and 8 (P < 0.001). No difference was found at week 1 (P = 0.4), 2 (P = 0.09), and 3 (P = 0.06). Figure 3 shows the results of cell migration at each follow-up.

Figure 3.

Figure 3

Open in a new tab

B-MSCs migration within the membrane.

Proliferation

The group without fibrin glue demonstrated greater proliferation of B-MSCs within the membrane. These differences were significant at week 4 (P < 0.0001), 6 (P < 0.0001), 8 (P < 0.0001). No difference was found at week 1 (P = 0.7), 2 (P = 0.8), 3 (P = 0.7). Figure 4 shows the results of cell proliferation at each follow-up.

Figure 4.

Figure 4

Open in a new tab

B-MSCs proliferation within the membrane.

Discussion

According to the main findings of the present in vitro study, the use of fibrin glue impairs B-MSCs proliferation and migration in a resorbable collagenic biomembrane routinely used in clinical practice (Figs. 5, 6). The no-glue membrane demonstrated in vitro greater migration of the B-MSCs within the membrane at week 4, 6, and 8 weeks and greater proliferation at all these follow-up times.

Figure 5.

Figure 5

Open in a new tab

Proliferation and migration of B-MSCs in the membrane without fibrin using the DAPI stained cell nuclei of B-MSCs (blue) assay. Time dependent proliferation and migration of B-MSCs into the non-fibrin treated membrane over 1, 2, 3, 4, 6, and 8 weeks (pictures a–f, respectively).

Figure 6.

Figure 6

Open in a new tab

Proliferation and migration in the fibrin glued membrane using the DAPI stained cell nuclei of B-MSCs (blue) assay. Time dependent proliferation and migration of B-MSCs into the non-fibrin treated membrane over the 1, 2, 3, 4, 6, and 8 weeks (pictures a–f, respectively).

Given their limited survival and unfavourable intra-articular environment which impairs cell colonisation, isolated microfractures of the subchondral bone are insufficient for cell engraftment25. Therefore, the membrane is supposed to protect the blood clot. The ideal properties of such membranes are biocompatibility and biodegradability, sufficient porosity to allow cell penetration, and permeability to permit both gas and nutrients delivery25. In addition, an ideal scaffold should permit extracellular matrix formation and the transmission of signalling molecules26. In the present experiment, we used resorbable collagen I/III porcine derived membranes which are commonly employed in chondral procedures22.

Collagen is the most abundant protein in the animal body27. It is a potential biomaterial scaffold for different tissue engineering applications27. Collagen is mechanically stable and has a high tensile strength. Different mechanisms are involved in the attachment of cells to collagens: Integrins play a key role in cell attachment27. The ∝ 1ß1 and ∝ 2ß1 integrins are the most important collagen binding integrins. ∝ 2ß1 has a high affinity for the fibrillar type I collagen, which is the major constituent protein of bone28. The ∝ 2ß1 integrin interaction with type I collagen signals the induction of both the osteoblastic differentiation and matrix mineralization28. Also, it was observed that ∝ 2ß1 integrin specific collagen-mimetic surfaces supports osteoblastic differentiation29. Altogether, a collagen scaffold offers the natural extracellular matrix environment with an intricate biochemical interplay, which promotes the proliferation and migration of B-MSCs27.

Several surgical procedures aiming to repair/regenerate chondral defects include the use of a biological resorbable membrane. Typically, during these procedures the membrane is fixed using sutures. This has been demonstrated to cause irreversible damage to the cartilage, which may lead to chronic pain and premature osteoarthritis30,31. Therefore, fibrin glue has been introduced to secure the membrane into the chondral defect. Fibrin is a tissue-derived natural component involved in the clotting process of blood25. Fibrin glue was initially employed for haemostasis on wounds by Bergel32. Since then, given its biological sealing, haemostatic, and adhesive proprieties, it has been widely used in various surgical fields33–36. Commercially available fibrin glues are prepared from allogeneic pooled plasma37. Fibrin glue commonly consists of a highly concentrated fibrinogen complex including fibrinogen, fibronectin, factor XIII, and plasminogen, and a high-potency thrombin34,38. Fibrin glues have been used for cell delivery, especially keratinocytes and fibroblasts39,40. Mainly through the action of thrombin, fibrin glue is believed to promote a variety of cellular responses, increasing cell migration, proliferation and survival41–45. However, in the present in vitro study, the addition of fibrin to a commercially resorbable biomembrane impaired B-MSCs proliferation and migration.

The exact mechanism of fibrin glue and its effect on MSC in vitro are largely unknown. In physiological tissue repair following damage, the platelet system is activated, and a fibrin matrix is formed after vasoconstriction and platelet clotting. Inflammatory cytokines, such as interleukin-1ß, tumour necrosis factor-α, and interferon-γ, are released by activated platelets46. However, in the present in vitro study, the addition of fibrin in a commercially resorbable biomembrane impaired B-MSCs proliferation and migration. Previous studies investigated the role of fibrin glue on colonic anastomoses in rats and demonstrated compromised healing following fibrin glue sealing47. Fibrin is presumed to impede macrophage migration48 and phagocytosis of bacteria by neutrophils49. We hypothesize that an increased inflammatory activity and immune response is promoted by fibrin glue, in accordance with earlier findings suggesting that fibrin can undergo degradative or inflammatory responses50. Previously, reduced collagen concentration caused by an increased production of collagenase from the inflammatory activity induced by fibrin glue has been reported51. Moreover, fibrin glue is supposed to stabilize growth factors, preventing the natural enzymatic degrading process52. Yet, a negative effect of high concentrations of growth factors in the production of neocartilage in vitro has been demonstrated53. So far, the in vitro concentrations of growth factors and their effects on prolifeating tissues have not been further examined53. Fibrin glue contains a high concentration of clotting factors but only a low number of stimulating factors54. Also, fibrin sealants might impair the migration of chondrocytes via a barrier effect55. Thus, it is possible to assumed that the proteins, cytokines, and B-MSC progenitor cells, which can be found in the joint intra-articular environment, might be enabled to proceed to the chondral surface. However, to date, their effect on cartilage repair in vitro and in vivo is not completely understood56.

A major disadvantage of fibrin glue is its difficulty in maintaining structural integrity, increasing instability and solubility over time from fibrinolysis57. Therefore, by 8 weeks, fibrin gel shrinkage and low mechanical stiffness might have contributed to the fact that fibrin in a resorbable collagenic biomembrane impaired B-MSCs proliferation and migration in our study.

This study certainly has limitations. The limited number of B-œ∆MSCs donors may negatively impact the reliability of the conclusion and increases the risk of publication bias. Moreover, the follow-up is limited to 8 weeks, thus impairing the capability to identify long term cells proliferation and migration. In such unperturbed experimental setting, cells migration and proliferation may not be realistic but preferred regions of migration creating higher density and therefore a false higher proliferation rate could be excluded to a degree by the highly standardized setting of the experiments. By definition, the intra-articular joint environment is complex, with many cell types, proteins, cytokines, solutions, and is subjected to heterogeneous pressures, contacts, and tensions. These factors may influence B-MSC migration, proliferation, and activity. Whether this membrane should be additionally fixed with fibrin, and how it interacts with B-MSCs proliferation and migration still remains unclear. Whether fibrin could promote macro- or microscopical structural changes in the collagenic membrane was not investigated in the present study. However, there were no evident alterations in the structure of the membranes at 8 weeks, suggesting no cytotoxic effect of the fibrin glue. The BMSCs used for the experiments were harvested from patients who underwent total hip arthroplasty for idiopathic joint osteoarthritis and agreed to donate their femoral head for this study. This procedure has been also validated in previous studies58–60. However, whether osteoarthritis affects B-MSCs migration and proliferation in our experimental setting is unknown. In addition, BMSCs harvested from the femoral head may be less active than those derived from the iliac crest or vertebrae in growth kinetics and chondrogenic differentiation61. We are aware that, given some evident limitations, such experimental study could not satisfactorily clarify these controversies; however, this work may contribute to develop future studies, and overcome current limitation to clinical translation.

Conclusion

In vitro, the use of fibrin in a resorbable collagen biomembrane impairs B-MSCs proliferation and migration.

Author contributions

F.M. conception and design, drafting, final approval; N.M.: supervision, revision, final approval; J.E.: supervision, final approval; C.W.: supervision, final approval; S.L.: experiments; J.P.: drafting, final approval; H.S.: drafting, final approval; F.H.: supervision, final approval; J.G.: conception, design, analysis, and interpretation of the data, drafting, final approval. All authors have agreed to the final version to be published and agree to be accountable for all aspects of the work.

Funding

Open Access funding enabled and organized by Projekt DEAL. The authors received no financial support for the research, authorship, and/or publication of this article.

Data availability

The datasets generated during and/or analysed during the current study are available throughout the manuscript.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Filippo Migliorini and Julia Prinz.

Contributor Information

Filippo Migliorini, Email: migliorini.md@gmail.com.

Nicola Maffulli, Email: n.maffulli@qmul.ac.uk.

References

  • 1.Robinson PG, Williamson T, Murray IR, Al-Hourani K, White TO. Sporting participation following the operative management of chondral defects of the knee at mid-term follow up: A systematic review and meta-analysis. J. Exp. Orthop. 2020;7(1):76. doi: 10.1186/s40634-020-00295-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Su CA, Trivedi NN, Le HT, Sivasundaram L, Maak TG, Salata MJ, Voos JE, Karns M. Clinical and radiographic outcomes after treatment of patellar chondral defects: A systematic review. Sports Health. 2021 doi: 10.1177/19417381211003515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Migliorini F, Eschweiler J, Schenker H, Baroncini A, Tingart M, Maffulli N. Surgical management of focal chondral defects of the knee: A Bayesian network meta-analysis. J. Orthop. Surg. Res. 2021;16(1):543. doi: 10.1186/s13018-021-02684-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Migliorini F, Berton A, Salvatore G, Candela V, Khan W, Longo UG, Denaro V. Autologous chondrocyte implantation and mesenchymal stem cells for the treatments of chondral defects of the knee—A systematic review. Curr. Stem Cell Res. Ther. 2020;15(6):547–556. doi: 10.2174/1574888X15666200221122834. [DOI] [PubMed] [Google Scholar]
  • 5.Migliorini F, Eschweiler J, Maffulli N, Driessen A, Rath B, Tingart M, Schenker H. Management of patellar chondral defects with Autologous Matrix Induced Chondrogenesis (AMIC) compared to microfractures: A four years follow-up clinical trial. Life (Basel). 2021 doi: 10.3390/life11020141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Migliorini F, Eschweiler J, Maffulli N, Schenker H, Baroncini A, Tingart M, Rath B. Autologous Matrix-Induced Chondrogenesis (AMIC) and microfractures for focal chondral defects of the knee: A medium-term comparative study. Life (Basel). 2021 doi: 10.3390/life11030183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Migliorini F, Eschweiler J, Maffulli N, Schenker H, Driessen A, Rath B, Tingart M. Autologous Matrix Induced Chondrogenesis (AMIC) compared to microfractures for chondral defects of the Talar shoulder: A five-year follow-up prospective cohort study. Life (Basel). 2021 doi: 10.3390/life11030244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tradati D, De Luca P, Maione A, Uboldi FM, Volpi P, de Girolamo L, Berruto M. AMIC-Autologous Matrix-Induced Chondrogenesis technique in patellar cartilage defects treatment: A retrospective study with a mid-term follow-up. J. Clin. Med. 2020 doi: 10.3390/jcm9041184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Migliorini F, Eschweiler J, Gotze C, Driessen A, Tingart M, Maffulli N. Matrix-induced autologous chondrocyte implantation (mACI) versus autologous matrix-induced chondrogenesis (AMIC) for chondral defects of the knee: A systematic review. Br. Med. Bull. 2022 doi: 10.1093/bmb/ldac004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Migliorini F, Maffulli N, Schenker H, Eschweiler J, Driessen A, Knobe M, Tingart M, Baroncini A. Surgical management of focal chondral defects of the talus: A Bayesian network meta-analysis. Am. J. Sports Med. 2021 doi: 10.1177/03635465211029642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gotze C, Nieder C, Felder H, Migliorini F. AMIC for focal osteochondral defect of the Talar shoulder. Life (Basel). 2020 doi: 10.3390/life10120328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gotze C, Nieder C, Felder H, Peterlein CD, Migliorini F. AMIC for traumatic focal osteochondral defect of the Talar shoulder: A 5 years follow-up prospective cohort study. BMC Musculoskelet. Disord. 2021;22(1):638. doi: 10.1186/s12891-021-04506-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chung JY, Lee DH, Kim TH, Kwack KS, Yoon KH, Min BH. Cartilage extra-cellular matrix biomembrane for the enhancement of microfractured defects. Knee Surg. Sports Traumatol. Arthrosc. 2014;22(6):1249–1259. doi: 10.1007/s00167-013-2716-4. [DOI] [PubMed] [Google Scholar]
  • 14.de Girolamo L, Schonhuber H, Vigano M, Bait C, Quaglia A, Thiebat G, Volpi P. Autologous Matrix-Induced Chondrogenesis (AMIC) and AMIC Enhanced by Autologous Concentrated Bone Marrow Aspirate (BMAC) allow for stable clinical and functional improvements at up to 9 years follow-up: Results from a randomized controlled study. J. Clin. Med. 2019 doi: 10.3390/jcm8030392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Buda R, Vannini F, Castagnini F, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G, Giannini S. Regenerative treatment in osteochondral lesions of the talus: Autologous chondrocyte implantation versus one-step bone marrow derived cells transplantation. Int. Orthop. 2015;39(5):893–900. doi: 10.1007/s00264-015-2685-y. [DOI] [PubMed] [Google Scholar]
  • 16.Giannini S, Buda R, Ruffilli A, Cavallo M, Pagliazzi G, Bulzamini MC, Desando G, Luciani D, Vannini F. Arthroscopic autologous chondrocyte implantation in the ankle joint. Knee Surg. Sports Traumatol. Arthrosc. 2014;22(6):1311–1319. doi: 10.1007/s00167-013-2640-7. [DOI] [PubMed] [Google Scholar]
  • 17.Giannini S, Buda R, Vannini F, Di Caprio F, Grigolo B. Arthroscopic autologous chondrocyte implantation in osteochondral lesions of the talus: Surgical technique and results. Am. J. Sports Med. 2008;36(5):873–880. doi: 10.1177/0363546507312644. [DOI] [PubMed] [Google Scholar]
  • 18.Niemeyer P, Laute V, John T, Becher C, Diehl P, Kolombe T, Fay J, Siebold R, Niks M, Fickert S, Zinser W. The effect of cell dose on the early magnetic resonance morphological outcomes of autologous cell implantation for articular cartilage defects in the knee: A randomized clinical trial. Am. J. Sports Med. 2016;44(8):2005–2014. doi: 10.1177/0363546516646092. [DOI] [PubMed] [Google Scholar]
  • 19.Niemeyer P, Laute V, Zinser W, Becher C, Kolombe T, Fay J, Pietsch S, Kuzma T, Widuchowski W, Fickert S. A prospective, randomized, open-label, multicenter, phase III noninferiority trial to compare the clinical efficacy of matrix-associated autologous chondrocyte implantation with spheroid technology versus arthroscopic microfracture for cartilage defects of the knee. Orthop. J. Sports Med. 2019;7(7):2325967119854442. doi: 10.1177/2325967119854442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Migliorini F, Maffulli N, Baroncini A, Knobe M, Tingart M, Eschweiler J. Matrix-induced autologous chondrocyte implantation versus autologous matrix-induced chondrogenesis for chondral defects of the talus: A systematic review. Br. Med. Bull. 2021;138(1):144–154. doi: 10.1093/bmb/ldab008. [DOI] [PubMed] [Google Scholar]
  • 21.Migliorini F, Eschweiler J, Spiezia F, van de Wall BJM, Knobe M, Tingart M, Maffulli N. Arthroscopy versus mini-arthrotomy approach for matrix-induced autologous chondrocyte implantation in the knee: A systematic review. J. Orthop. Traumatol. 2021;22(1):23. doi: 10.1186/s10195-021-00588-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Migliorini F, Eschweiler J, Goetze C, Tingart M, Maffulli N. Membrane scaffolds for matrix-induced autologous chondrocyte implantation in the knee: A systematic review. Br. Med. Bull. 2021;140(1):50–61. doi: 10.1093/bmb/ldab024. [DOI] [PubMed] [Google Scholar]
  • 23.Migliorini F, Prinz J, Maffulli N, Eschweiler J, Weber C, Lecoutrier S, Hildebrand F, Greven J, Schenker H. Fibrin glue does not assist migration and proliferation of chondrocytes in collagenic membranes: An in vitro study. J. Orthop. Surg. Res. 2022;17(1):311. doi: 10.1186/s13018-022-03201-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Li H, Ghazanfari R, Zacharaki D, Lim HC, Scheding S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann. N. Y. Acad. Sci. 2016;1370(1):109–118. doi: 10.1111/nyas.13102. [DOI] [PubMed] [Google Scholar]
  • 25.Kim YS, Choi YJ, Suh DS, Heo DB, Kim YI, Ryu JS, Koh YG. Mesenchymal stem cell implantation in osteoarthritic knees: Is fibrin glue effective as a scaffold? Am. J. Sports Med. 2015;43(1):176–185. doi: 10.1177/0363546514554190. [DOI] [PubMed] [Google Scholar]
  • 26.Nöth U, Steinert AF, Tuan RS. Technology insight: Adult mesenchymal stem cells for osteoarthritis therapy. Nat. Clin. Pract. Rheumatol. 2008;4(7):371–380. doi: 10.1038/ncprheum0816. [DOI] [PubMed] [Google Scholar]
  • 27.George J, Kuboki Y, Miyata T. Differentiation of mesenchymal stem cells into osteoblasts on honeycomb collagen scaffolds. Biotechnol. Bioeng. 2006;95(3):404–411. doi: 10.1002/bit.20939. [DOI] [PubMed] [Google Scholar]
  • 28.Mizuno M, Kuboki Y. Osteoblast-related gene expression of bone marrow cells during the osteoblastic differentiation induced by type I collagen. J. Biochem. 2001;129(1):133–138. doi: 10.1093/oxfordjournals.jbchem.a002824. [DOI] [PubMed] [Google Scholar]
  • 29.Reyes CD, García AJ. Alpha2beta1 integrin-specific collagen-mimetic surfaces supporting osteoblastic differentiation. J. Biomed. Mater. Res. A. 2004;69(4):591–600. doi: 10.1002/jbm.a.30034. [DOI] [PubMed] [Google Scholar]
  • 30.Walker EA, Verner A, Flannery CR, Archer CW. Cellular responses of embryonic hyaline cartilage to experimental wounding in vitro. J. Orthop. Res. 2000;18(1):25–34. doi: 10.1002/jor.1100180105. [DOI] [PubMed] [Google Scholar]
  • 31.Hunziker EB, Quinn TM. Surgical removal of articular cartilage leads to loss of chondrocytes from cartilage bordering the wound edge. J. Bone Joint Surg. Am. 2003;85-A(Suppl 2):85–92. doi: 10.2106/00004623-200300002-00011. [DOI] [PubMed] [Google Scholar]
  • 32.Bergel S. Über Wirkungen des Fibrins. Dtsch Med Wochenschr. 1909;35:663. doi: 10.1055/s-0029-1201395. [DOI] [Google Scholar]
  • 33.Buchta C, Dettke M, Funovics PT, Höcker P, Knöbl P, Macher M, Quehenberger P, Treitl C, Worel N. Fibrin sealant produced by the CryoSeal FS System: Product chemistry, material properties and possible preparation in the autologous preoperative setting. Vox. Sang. 2004;86(4):257–262. doi: 10.1111/j.0042-9007.2004.00516.x. [DOI] [PubMed] [Google Scholar]
  • 34.Catelas I, Sese N, Wu BM, Dunn JC, Helgerson S, Tawil B. Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro. Tissue Eng. 2006;12(8):2385–2396. doi: 10.1089/ten.2006.12.2385. [DOI] [PubMed] [Google Scholar]
  • 35.Morales-Conde S, Balla A, Alarcon I, Sanchez-Ramirez M. Minimally invasive repair of ventral hernia with one third of tackers and fibrin glue: less pain and same recurrence rate. Minerva Chir. 2020;75(5):292–297. doi: 10.23736/S0026-4733.20.08468-0. [DOI] [PubMed] [Google Scholar]
  • 36.Wong AI, McDonald A, Jones B, Berkowitz D. Patch-and-glue: Novel technique in bronchoesophageal fistula repair and broncholith removal with stent and fibrin glue. J. Bronchol. Interv. Pulmonol. 2020 doi: 10.1097/LBR.0000000000000732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Buchta C, Hedrich HC, Macher M, Höcker P, Redl H. Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel. Biomaterials. 2005;26(31):6233–6241. doi: 10.1016/j.biomaterials.2005.04.014. [DOI] [PubMed] [Google Scholar]
  • 38.Marx G. Evolution of fibrin glue applicators. Transfus. Med. Rev. 2003;17(4):287–298. doi: 10.1016/s0887-7963(03)00041-5. [DOI] [PubMed] [Google Scholar]
  • 39.Horch RE, Bannasch H, Kopp J, Andree C, Stark GB. Single-cell suspensions of cultured human keratinocytes in fibrin-glue reconstitute the epidermis. Cell Transpl. 1998;7(3):309–317. doi: 10.1016/s0963-6897(98)00005-0. [DOI] [PubMed] [Google Scholar]
  • 40.Gorodetsky R, Clark RA, An J, Gailit J, Levdansky L, Vexler A, Berman E, Marx G. Fibrin microbeads (FMB) as biodegradable carriers for culturing cells and for accelerating wound healing. J. Invest. Dermatol. 1999;112(6):866–872. doi: 10.1046/j.1523-1747.1999.00600.x. [DOI] [PubMed] [Google Scholar]
  • 41.Karp JM, Tanaka TS, Zohar R, Sodek J, Shoichet MS, Davies JE, Stanford WL. Thrombin mediated migration of osteogenic cells. Bone. 2005;37(3):337–348. doi: 10.1016/j.bone.2005.04.022. [DOI] [PubMed] [Google Scholar]
  • 42.Brown LF, Lanir N, McDonagh J, Tognazzi K, Dvorak AM, Dvorak HF. Fibroblast migration in fibrin gel matrices. Am. J. Pathol. 1993;142(1):273–283. [PMC free article] [PubMed] [Google Scholar]
  • 43.Tani K, Yasuoka S, Ogushi F, Asada K, Fujisawa K, Ozaki T, Sano N, Ogura T. Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 1991;5(1):34–40. doi: 10.1165/ajrcmb/5.1.34. [DOI] [PubMed] [Google Scholar]
  • 44.Chinni C, de Niese MR, Tew DJ, Jenkins AL, Bottomley SP, Mackie EJ. Thrombin, a survival factor for cultured myoblasts. J. Biol. Chem. 1999;274(14):9169–9174. doi: 10.1074/jbc.274.14.9169. [DOI] [PubMed] [Google Scholar]
  • 45.Pagel CN, de Niese MR, Abraham LA, Chinni C, Song SJ, Pike RN, Mackie EJ. Inhibition of osteoblast apoptosis by thrombin. Bone. 2003;33(4):733–743. doi: 10.1016/s8756-3282(03)00209-6. [DOI] [PubMed] [Google Scholar]
  • 46.Giusti I, D'Ascenzo S, Macchiarelli G, Dolo V. In vitro evidence supporting applications of platelet derivatives in regenerative medicine. Blood Transfus. 2020;18(2):117–129. doi: 10.2450/2019.0164-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ozel SK, Kazez A, Akpolat N. Does a fibrin-collagen patch support early anastomotic healing in the colon? An experimental study. Tech. Coloproctol. 2006;10(3):233–236. doi: 10.1007/s10151-006-0285-y. [DOI] [PubMed] [Google Scholar]
  • 48.Ciano PS, Colvin RB, Dvorak AM, McDonagh J, Dvorak HF. Macrophage migration in fibrin gel matrices. Lab. Invest. 1986;54(1):62–70. [PubMed] [Google Scholar]
  • 49.Rotstein OD, Pruett TL, Simmons RL. Fibrin in peritonitis. V. Fibrin inhibits phagocytic killing of Escherichia coli by human polymorphonuclear leukocytes. Ann. Surg. 1986;203(4):413–419. doi: 10.1097/00000658-198604000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Haisch A, Loch A, David J, Pruss A, Hansen R, Sittinger M. Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering. Med. Biol. Eng. Comput. 2000;38(6):686–689. doi: 10.1007/bf02344876. [DOI] [PubMed] [Google Scholar]
  • 51.van der Ham AC, Kort WJ, Weijma IM, Jeekel H. Transient protection of incomplete colonic anastomoses with fibrin sealant: An experimental study in the rat. J. Surg. Res. 1993;55(3):256–260. doi: 10.1006/jsre.1993.1137. [DOI] [PubMed] [Google Scholar]
  • 52.Kaufman MR, Westreich R, Ammar SM, Amirali A, Iskander A, Lawson W. Autologous cartilage grafts enhanced by a novel transplant medium using fibrin sealant and fibroblast growth factor. Arch Facial Plast. Surg. 2004;6(2):94–100. doi: 10.1001/archfaci.6.2.94. [DOI] [PubMed] [Google Scholar]
  • 53.Westreich R, Kaufman M, Gannon P, Lawson W. Validating the subcutaneous model of injectable autologous cartilage using a fibrin glue scaffold. Laryngoscope. 2004;114(12):2154–2160. doi: 10.1097/10.mlg.0000149449.37640.0d. [DOI] [PubMed] [Google Scholar]
  • 54.Brittberg M, Sjögren-Jansson E, Lindahl A, Peterson L. Influence of fibrin sealant (Tisseel) on osteochondral defect repair in the rabbit knee. Biomaterials. 1997;18(3):235–242. doi: 10.1016/s0142-9612(96)00117-2. [DOI] [PubMed] [Google Scholar]
  • 55.Cheung HS, Lynch KL, Johnson RP, Brewer BJ. In vitro synthesis of tissue-specific type II collagen by healing cartilage. I. Short-term repair of cartilage by mature rabbits. Arthritis Rheum. 1980;23(2):211–219. doi: 10.1002/art.1780230212. [DOI] [PubMed] [Google Scholar]
  • 56.Mak J, Jablonski CL, Leonard CA, Dunn JF, Raharjo E, Matyas JR, Biernaskie J, Krawetz RJ. Intra-articular injection of synovial mesenchymal stem cells improves cartilage repair in a mouse injury model. Sci. Rep. 2016;6:23076. doi: 10.1038/srep23076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Huang S, Fu X. Naturally derived materials-based cell and drug delivery systems in skin regeneration. J. Control Release. 2010;142(2):149–159. doi: 10.1016/j.jconrel.2009.10.018. [DOI] [PubMed] [Google Scholar]
  • 58.Niedermair T, Lukas C, Li S, Stockl S, Craiovan B, Brochhausen C, Federlin M, Herrmann M, Grassel S. Influence of extracellular vesicles isolated from osteoblasts of patients with cox-arthrosis and/or osteoporosis on metabolism and osteogenic differentiation of BMSCs. Front. Bioeng. Biotechnol. 2020;8:615520. doi: 10.3389/fbioe.2020.615520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Chen G, Wang Q, Li Z, Yang Q, Liu Y, Du Z, Zhang G, Song Y. Circular RNA CDR1as promotes adipogenic and suppresses osteogenic differentiation of BMSCs in steroid-induced osteonecrosis of the femoral head. Bone. 2020;133:115258. doi: 10.1016/j.bone.2020.115258. [DOI] [PubMed] [Google Scholar]
  • 60.Ilas DC, Baboolal TG, Churchman SM, Jones WG, Giannoudis PV, Buhring HJ, McGonagle D, Jones E. The osteogenic commitment of CD271+CD56+ bone marrow stromal cells (BMSCs) in osteoarthritic femoral head bone. Sci. Rep. 2020;10(1):11145. doi: 10.1038/s41598-020-67998-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Herrmann M, Hildebrand M, Menzel U, Fahy N, Alini M, Lang S, Benneker L, Verrier S, Stoddart MJ, Bara JJ. Phenotypic characterization of bone marrow mononuclear cells and derived stromal cell populations from human iliac crest, vertebral body and femoral head. Int. J. Mol. Sci. 2019 doi: 10.3390/ijms20143454. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated during and/or analysed during the current study are available throughout the manuscript.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES